Sera Prognostics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sera Prognostics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 92% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-34.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 67% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 70%
Sales fell 70% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-70% / -12%In 3 years sales changed by -70% while total assets changed by -12%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-12,811.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+46%Cash, after subtracting all debt, equals 46% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 90% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Sera Prognostics, Inc. made a loss over the last year. Sera Prognostics, Inc. owes $0.32 for every $1 it owns. Sera Prognostics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSera Prognostics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.36The share price is 1.36 times Sera Prognostics, Inc.'s book value per share, lower than 70% of Healthcare companies in United States.
Market cap
$80 MThe total market value of all of Sera Prognostics, Inc.'s shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$59 MWhat Sera Prognostics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.51Net worth divided by the number of shares. The share price of $2.04 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
-45.0%Sera Prognostics, Inc. lost 45.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
Owes vs Owns
0.32×Sera Prognostics, Inc. owes $0.32 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Dividend yield
NoneSera Prognostics, Inc. does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Dec 2025, and shrank 33% a year on average over 3 years.
Profit growth
LossSera Prognostics, Inc. made a loss in each of the last two years.
Profit margin
-39417.3%Sera Prognostics, Inc. lost $39417 for every $100 of revenue.
Interest cover
Not coveredSera Prognostics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSera Prognostics, Inc. held $37 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sera Prognostics, Inc.: $80 M ÷ $59 M (30 Jun 2026) = 1.4.
What is Sera Prognostics, Inc.'s return on equity?
Sera Prognostics, Inc. lost 45.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
How much does Sera Prognostics, Inc. owe compared with what it owns?
Sera Prognostics, Inc. owes $0.32 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Does Sera Prognostics, Inc. pay a dividend?
No. Sera Prognostics, Inc. does not currently pay a dividend.
Is Sera Prognostics, Inc.'s revenue growing?
Revenue rose 5% in the year to Dec 2025, and shrank 33% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.